Castle Biosciences to Present at the Baird 2019 Global Healthcare Conference
August 27 2019 - 7:00AM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL) today announced that
Derek Maetzold, President and Chief Executive Officer, is scheduled
to present a company overview at the Baird 2019 Global Healthcare
Conference in New York City on Wednesday, September 4, 2019, at
2:00 p.m. Eastern time.
A live audio webcast of the company’s presentation will be
available by visiting Castle Biosciences’ website at
https://ir.castlebiosciences.com/news-events/events-presentations.
A replay of the webcast will be available for two weeks following
the conclusion of the live broadcast.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a commercial-stage
dermatologic cancer company focused on providing physicians and
their patients with personalized, clinically actionable genomic
information to make more accurate treatment decisions. The Company
currently offers tests for patients with cutaneous melanoma
(DecisionDx®-Melanoma, DecisionDx®-CMSeq; www.SkinMelanoma.com) and
uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and
DecisionDx®-UMSeq; www.MyUvealMelanoma.com), with products in
development for other underserved cancers, the two most advanced of
which are focused on patients with cutaneous squamous cell
carcinoma, and patients who have a difficult-to-diagnose pigmented
lesion. Castle Biosciences is based in Friendswood, Texas
(Houston), and has laboratory operations in Phoenix, Arizona. For
more information, visit www.CastleBiosciences.com.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are the trademarks of Castle
Biosciences, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190827005263/en/
Frank Stokes, CFO 866-788-9007 IR@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Apr 2023 to Apr 2024